	US 12,240,915 B2
	Chimeric antigen receptor cells for treating solid tumor
Lei Xiao, Rockville, MD (US); He Sun, Shanghai (CN); Zhiyuan Cao, Shanghai (CN); Wensheng Wang, Shanghai (CN); Chengfei Pu, Shanghai (CN); and Li Mao, Shanghai (CN)
Assigned to Innovative Cellular Therapeutics Holdings, Ltd., George Town (KY); and Innovative Cellular Therapeutics, Inc., Rockville, MD (US)
Appl. No. 17/270,571
Filed by Innovative Cellular Therapeutics Holdings, Ltd., Grand Cayman (KY); and Innovative Cellular Therapeutics, Inc., Rockville, MD (US)
PCT Filed Aug. 29, 2019, PCT No. PCT/US2019/048890 § 371(c)(1), (2) Date Feb. 23, 2021, PCT Pub. No. WO2020/047306, PCT Pub. Date Mar. 5, 2020.
Claims priority of provisional application 62/848,984, filed on May 16, 2019.
Claims priority of provisional application 62/842,936, filed on May 3, 2019.
Claims priority of provisional application 62/807,482, filed on Feb. 19, 2019.
Claims priority of provisional application 62/754,175, filed on Nov. 1, 2018.
Claims priority of provisional application 62/731,079, filed on Sep. 13, 2018.
Claims priority of provisional application 62/725,025, filed on Aug. 30, 2018.
Prior Publication US 2022/0348682 A1, Nov. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/40 (2006.01); A61K 47/68 (2017.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01)

CPC C07K 16/40 (2013.01) [A61K 47/6801 (2017.08); A61K 47/6869 (2017.08); C07K 14/7051 (2013.01); C07K 16/3069 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/03 (2013.01)]

19 Claims

1. An antibody that binds ACPP, wherein the antibody comprises

(a) a light chain variable region (LVR) comprising amino acid sequence SEQ ID NO: 82 and a heavy chain variable region (HVR) comprising amino acid sequence SEQ ID NO: 83;

(b) an LVR comprising amino acid sequence SEQ ID NO: 84 and an HVR comprising amino acid sequence SEQ ID NO: 85;

(d) an LVR comprising amino acid sequence SEQ ID NO: 88 and an HVR comprising amino acid sequence SEQ ID NO: 89.